FABP7 has also been shown to be highly expressed in NSCLC patient tumor cells, and studies in NSCLC cell lines indicate that FABP7 exerts prometastatic effects via impaired β-catenin degradation leading to Wnt hyperactivation (9). This evidence concerns the gene FABP7 and non-small cell lung carcinoma.